SCHEMBL14375860

SCHEMBL14375860

Cc1ncc(/C=C2\C(=O)Nc3ccc(Cl)cc32)[nH]1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.69
▸ GAA P10253 1/20 0.69
▸ MAPT P10636 1/20 0.69
▸ KMT2A Q03164 1/20 0.69
▸ TDP1 Q9NUW8 1/20 0.69
▸ LRRK2 Q5S007 7/20 0.67
▸ RET P07949 1/20 0.59
▸ PDGFRB P09619 2/20 0.58
▸ MAP4K1 Q92918 3/20 0.54
▸ PSEN1 P49768 2/20 0.53
▸ PSEN2 P49810 2/20 0.53
▸ APH1B Q8WW43 2/20 0.53
▸ NCSTN Q92542 2/20 0.53
▸ APH1A Q96BI3 2/20 0.53
▸ PSENEN Q9NZ42 2/20 0.53
▸ PAK4 O96013 1/20 0.53
▸ IDO1 P14902 1/20 0.52
▸ TDO2 P48775 1/20 0.52
▸ TGM2 P21980 1/20 0.52
▸ RPS6KA3 P51812 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15879182 1.00 NPC1 (0.69) NPC1GAAMAPTKMT2ATDP1
SCHEMBL14335878 0.85 KMT2A (0.69) NPC1GAAMAPTKMT2ATDP1
SCHEMBL14335879 0.85 KMT2A (0.69) NPC1GAAMAPTKMT2ATDP1
SCHEMBL14376556 0.84 NPC1 (0.71) NPC1GAAMAPTKMT2ATDP1
SCHEMBL14376348 0.83 LRRK2 (0.78) NPC1GAAMAPTKMT2ATDP1
SCHEMBL15878619 0.83 LRRK2 (0.78) NPC1GAAMAPTKMT2ATDP1
SCHEMBL14375854 0.82 NPC1 (0.65) NPC1GAAMAPTKMT2ATDP1
SCHEMBL15877629 0.82 NPC1 (0.65) NPC1GAAMAPTKMT2ATDP1
SCHEMBL14375839 0.81 LRRK2 (0.74) NPC1GAAMAPTKMT2ATDP1
SCHEMBL15877989 0.81 LRRK2 (0.74) NPC1GAAMAPTKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140205537-A1 LRRK2 INHIBITORS ZENOBIA THERAPEUTICS, INC. (US) 2014-07-24 — — US claimed
US-20140205537-A1 LRRK2 INHIBITORS ZENOBIA THERAPEUTICS, INC. (US) 2014-07-24 — — US disclosed
US-20140205537-A1 LRRK2 INHIBITORS ZENOBIA THERAPEUTICS, INC. (US) 2014-07-24 — — US disclosed
WO-2012178015-A2 LRRK2 INHIBITORS ZENOBIA THERAPEUTICS, INC. (US) 2012-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140205537-A1 LRRK2 INHIBITORS LRRK2, PARK7, MAP2 NPC1 875/4885GAA 872/4885MAPT 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback